Login to Your Account



Pharma: Clinic Roundup


Tuesday, May 29, 2012
• Pfizer Inc., of New York, said the European Medicines Agency's Committee for Human Medicinal Products recommended marketing authorization for axitinib as a second-line treatment for adults with advanced renal cell carcinoma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription